Eli Lilly: Alzheimer drug trial discontinued
(CercleFinance.com) - Shares of Eli Lilly are down in early morning on Tuesday, after the company said it was discontinuing two Phase III trials for an experimental Alzheimer's disease drug developed with British partner AstraZeneca.
The decision was based on recommendations by an independent data monitoring committee, which concluded that the trials, both in early Alzheimer's disease and mild Alzheimer's disease dementia, were unlikely to meet their primary endpoints.
The primary endpoints of the trials were changes in several aspects of cognition for the patients.
Shares in Eli Lilly are currently down 0.1% at 85.8 dollars.
Copyright (c) 2018 CercleFinance.com. All rights reserved.